NASDAQ · ONVO
Healthcare · Biotechnology
$2.04
Up+$0.03 (+1.49%)
Updated Oct 8, 2026, 4:56 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ONVO
1M range · 0 trading sessions · Daily adjusted prices
ONVO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ONVO.
Company
Market Activity
Research & News
ONVO research
Company profile and research snapshot.
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 8, 2019 | H.C. Wainwright | Neutral | — |
| Dec 13, 2018 | H.C. Wainwright | Buy | — |
| Nov 10, 2017 | Raymond James | Market Perform | — |
| Jan 25, 2017 | Raymond James | Outperform | — |
| Dec 15, 2016 | BTIG Research | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Feb 27, 2025
The global human liver model market is projected to grow at a CAGR of 14.04% from 2025 to 2030, driven by the increasing prevalence of liver diseases, advancements in organ printing technologies, and increased demand for liver cancer therapeutics.
The Motley Fool · Feb 25, 2025
Eli Lilly announced plans to acquire Organovo's FXR program and launched larger-dose vials of its weight loss drug Zepbound at lower prices, causing its stock to rise 2.6% despite a market downturn.
GlobeNewswire Inc. · May 21, 2024
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
GlobeNewswire Inc. · May 14, 2024
Organovo will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ONVO.
No results
No recent SID articles mention ONVO.
